# Indapamide

Drug · id `cardio:indapamide` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, organ or system: Heart; Kidneys  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

Indapamide is a thiazide-like diuretic taken by mouth. The US label read is for indapamide tablets and lists two uses: the treatment of hypertension, alone or in combination with other antihypertensive drugs, and the treatment of salt and fluid retention associated with congestive heart failure. No brand-name indapamide label was found in openFDA, so this page rests on a generic manufacturer's label. The label's separate passage on diuretics in pregnancy was not recorded.

## Technical summary

RxNorm ingredient 5764; UNII F089I0511L. MeSH descriptor D007190 is Indapamide. Class: Thiazide-like Diuretic (FDA established pharmacologic class, RxClass). The label read is the indapamide tablets, Rising Pharma Holdings, Inc. label, effective 2023-06-26 in openFDA (application ANDA074461). Other indapamide labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of indapamide tablets, in the Rising Pharma Holdings, Inc. version dated 2023-06-26 in openFDA, lists the medicine for the treatment of hypertension, alone or in combination with other antihypertensive drugs, and for the treatment of salt and fluid retention associated with congestive heart failure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for indapamide tablets, Rising Pharma Holdings, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 0687ed93-4761-4f9c-887d-95309c03f60e (manufacturer Rising Pharma Holdings, Inc., application ANDA074461), returned on 2026-11-09. The label text is dated 2023-06-26 (effective\_time). Other openFDA records of indapamide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220687ed93-4761-4f9c-887d-95309c03f60e%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-09T13:18:11Z. Source state: Current. Version fingerprint: f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for indapamide tablets, Rising Pharma Holdings, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 0687ed93-4761-4f9c-887d-95309c03f60e (manufacturer Rising Pharma Holdings, Inc., application ANDA074461), returned on 2026-11-09. The label text is dated 2023-06-26 (effective\_time). Other openFDA records of indapamide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220687ed93-4761-4f9c-887d-95309c03f60e%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:11Z. Source state: Current. Version fingerprint: f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43.
     How it applies: Effective date of the label text read, 20230626.

## Connected pages

- Indapamide is a thiazide-like diuretic (FDA established pharmacologic class in RxClass): Thiazide and thiazide-like diuretics (`cardio:thiazide-and-thiazide-like-diuretics`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-indapamide-label-indications` and its context]
- FDA label lists the treatment of salt and fluid retention associated with congestive heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-indapamide-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 3 registry trials

## Provenance

Content hash: fd18e64fc98c979899df809427ca829d29c921ea8394766c35f548e227a22ec1
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
